Clinical development of synthetic siRNA therapeutics

Drug Discovery Today: Therapeutic Strategies

Volumn 10, Issue 3, 2013, Pages e133-e138

  Thompson, James D ^a  

^a QBI Enterprises Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877130036     PISSN: None     EISSN: 17406773     Source Type: Journal    
DOI: 10.1016/j.ddstr.2013.03.002     Document Type: Review

References (37)

1. Fire, A. et al. (1998) Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature 391, 806-811
2. Mello, C.C. and Conte, D., Jr (2004) Revealing the world of RNA interference. Nature 431, 338-342
3. Wang, Y. et al. (2011) dsRNA sensors and plasmacytoid dendritic cells in host defense and autoimmunity. Immunol. Rev. 243, 74-90
4. Bernstein, E. et al. (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363-366
5. Elbashir, S.M. et al. (2001) RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev. 15, 188-200
6. Elbashir, S.M. et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498
7. McManus, M.T. and Sharp, P.A. (2002) Gene silencing in mammals by small interfering RNAs. Nat. Rev. Genet. 3, 737-747
8. Ambros, V. (2011) MicroRNAs and developmental timing. Curr. Opin. Genet. Dev. 21, 511-517
9. Valencia-Sanchez, M.A. et al. (2006) Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20, 515-524
10. Schwarz, D.S. et al. (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199-208
11. Schwarz, D.S. et al. (2002) Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol. Cell 10, 537-548
12. Birmingham, A. et al. (2006) 30 UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3, 199-204
13. Jackson, A.L. et al. (2006) Position-specific chemical modification of siRNAs reduces 'off-target' transcript silencing. RNA 12, 1197-1205
14. Behlke, M.A. (2006) Progress towards in vivo use of siRNAs. Mol. Ther. 13, 644-670
15. Rettig, G.R. and Behlke, M.A. (2012) Progress toward in vivo use of siRNAs-II. Mol. Ther. 20, 483-512
16. Judge, A. and MacLachlan, I. (2008) Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther. 19, 111-124
17. Robbins, M. et al. (2009) siRNA and innate immunity. Oligonucleotides 19, 89-102
18. Dejneka, N.S. et al. (2008) Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. Mol. Vis. 14, 997-1005
19. Lee, D.U. et al. (2012) Retina expression and cross-species validation of gene silencing by PF-655, a small interfering RNA against RTP801 for the treatment of ocular disease. J. Ocul. Pharmacol. Ther. 28, 222-230
20. Alvarez, R. et al. (2009) RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob. Agents Chemother. 53, 3952-3962
21. Molitoris, B.A. et al. (2009) siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. J. Am. Soc. Nephrol. 20, 1754-1764
22. Thompson, J.D. et al. (2012) Toxicological and pharmacokinetic properties of chemically modified siRNAs pargeting p53 RNA following intravenous administration. Nucleic Acid Ther. 22, 255-264
23. Yu, B. et al. (2009) Targeted delivery systems for oligonucleotide therapeutics. AAPS J. 11, 195-203
24. Semple, S.C. et al. (2010) Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172-176
25. Barros, S. and Gollob, J. (2012) Safety profile of RNAi nanomedicines. Adv. Drug Deliv. Rev. 64, 1730-1737
26. Davis, M.E. (2009) The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6, 659-668
27. Singerman, L. (2009) Combination therapy using the small interfering RNA bevasiranib. Retina 29 (Suppl), S49-S50
28. Kaiser, P.K. et al. (2010) RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. Am. J. Ophthalmol. 150, 33-39
29. Shoshani, T. et al. (2002) Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell. Biol. 22, 2283-2293
30. Nguyen, Q.D. et al. (2012) Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients. Eye 26, 1099-1105
31. DEGAS Study, ClinicalTrials.gov Identifier NCT00701181
32. ClinicalTrials.gov Identifier NCT01445899
33. ClincalTrials.gov Identifier NCT00395057
34. ClinicalTrials.gov Identifier NCT00499590
35. Davis, M.E. et al. (2010) Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070
36. Cervantes, A. et al. (2011) Phase I dose-escalation study of ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement. J Clin Oncol 29 (suppl, abstr 3025)
37. Crooke, S. (2007) Antisense Drug Technology: Principles, Strategies, and Applications (2nd edn), CRC Press